| Drug-perturbation-based stratification of blood cancer S Dietrich, M Oleś, J Lu, L Sellner, S Anders, B Velten, B Wu, J Huellein, ... The Journal of clinical investigation 128 (1), 427-445, 2018 | 150 | 2018 |
| High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells S Oppermann, J Ylanko, Y Shi, S Hariharan, CC Oakes, PM Brauer, ... Blood, The Journal of the American Society of Hematology 128 (7), 934-947, 2016 | 116 | 2016 |
| Molecular pathways: leveraging the BCL-2 interactome to kill cancer cells—mitochondrial outer membrane permeabilization and beyond H Brahmbhatt, S Oppermann, EJ Osterlund, B Leber, DW Andrews Clinical Cancer Research 21 (12), 2671-2676, 2015 | 38 | 2015 |
| Novel N-phenyl–substituted thiazolidinediones protect neural cells against glutamate-and tBid-induced toxicity S Oppermann, FC Schrader, K Elsässer, AM Dolga, AL Kraus, N Doti, ... Journal of Pharmacology and Experimental Therapeutics 350 (2), 273-289, 2014 | 24 | 2014 |
| Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells S Oppermann, AJ Lam, S Tung, Y Shi, L McCaw, G Wang, J Ylanko, ... Oncotarget 7 (45), 72608, 2016 | 17 | 2016 |
| Functional therapeutic target validation using pediatric zebrafish xenograft models C Gatzweiler, J Ridinger, S Herter, XF Gerloff, D ElHarouni, Y Berker, ... Cancers 14 (3), 849, 2022 | 15 | 2022 |
| iTReX: Interactive exploration of mono-and combination therapy dose response profiling data D ElHarouni, Y Berker, H Peterziel, A Gopisetty, L Turunen, S Kreth, ... Pharmacological research 175, 105996, 2022 | 13 | 2022 |
| BID links ferroptosis to mitochondrial cell death pathways. Redox Biol 12: 558–570 S Neitemeier, A Jelinek, V Laino, L Hoffmann, I Eisenbach, R Eying, ... | 12 | 2017 |
| Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM H Peterziel, N Jamaladdin, D ElHarouni, XF Gerloff, S Herter, P Fiesel, ... NPJ precision oncology 6 (1), 94, 2022 | 11 | 2022 |
| Apoptosis and beyond: the many ways cells die JA Radosevich John Wiley & Sons, 2018 | 10 | 2018 |
| Molecular mechanisms underlying oxytosis AM Dolga, S Oppermann, M Richter, B Honrath, S Neitemeier, A Jelinek, ... Apoptosis and beyond, 289-316, 2018 | 7 | 2018 |
| Patient-by-Patient deep transfer learning for drug-response profiling using confocal fluorescence microscopy of pediatric patient-derived tumor-cell spheroids Y Berker, D ElHarouni, H Peterziel, P Fiesel, O Witt, I Oehme, M Schlesner, ... IEEE Transactions on Medical Imaging 41 (12), 3981-3999, 2022 | 6 | 2022 |
| BID links ferroptosis to mitochondrial cell death pathways, Redox. Biol. 12 (2017) 558–570 S Neitemeier, A Jelinek, V Laino, L Hoffmann, I Eisenbach, R Eying, ... | 6 | 2019 |
| Identification of kinase inhibitors that overcome venetoclax resistance in activated CLL cells by high-content screening S Oppermann, J Ylanko, Y Shi, S Hariharan, CC Oakes, PM Brauer, ... Blood 12, 8-15, 2016 | 5 | 2016 |
| Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells S Zeuner, J Vollmer, R Sigaud, S Oppermann, H Peterziel, D ElHarouni, ... Journal of Neuro-oncology, 1-14, 2024 | 1 | 2024 |
| Interaction between BID and VDAC1 is required for mitochondrial demise and cell death in neurons S Oppermann, B Mertins, L Meissner, C Krasel, G Psakis, P Reiß, ... bioRxiv, 2021.09. 14.460262, 2021 | 1 | 2021 |
| Targeting Bid for mitoprotection-Bid crystallization, new mechanisms and inhibitory compounds S Oppermann Philipps-Universität Marburg, 2014 | 1 | 2014 |
| Synergistic drug combinations for the treatment of MYC amplified medulloblastoma S Zeuner, J Vollmer, S Oppermann, I Oehme, H Peterziel, D ElHarouni, ... Klinische Pädiatrie 235 (06), 2023 | | 2023 |
| OTHR-04. DEVELOPMENT OF A FUNCTIONAL PLATFORM FOR REAL-TIME PERSONALIZED DRUG SENSITIVITY PROFILING OF PATIENT-DERIVED 3D FRESH TUMOR TISSUE CULTURES IN THE PEDIATRIC PRECISION … H Peterziel, N Jamaladdin, D ElHarouni, XF Gerloff, S Herter, P Fiesel, ... Neuro-Oncology 25 (Supplement_1), i74-i75, 2023 | | 2023 |
| Multiomics analysis of pediatric solid tumors within the INFORM precision oncology study: From functional drug profiling to biomarker identification. D ElHarouni, H Peterziel, K Schramm, T Milde, S Oppermann, I Oehme, ... Journal of Clinical Oncology 40 (16_suppl), 10036-10036, 2022 | | 2022 |
